In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...

Shares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on ...

Canaccord Genuity analyst William Maughan maintained a Buy rating and increased the price target from $171 to $171.44 on Nov. 27, 2024. This analyst has an accuracy rate of 71%. JP Morgan analyst ...

BioNTech (NASDAQ:BNTX – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of $0.38 per ...

BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...

SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings ...

The benchmark US stock measures were trending lower before Monday's opening bell as traders await fresh inflation data later in the week. Standard & Poor's 500 declined 1.1%, the Dow Jones Industrial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

MRNA's Court Victory A German court ruled that BioNTech (BNTX) and Pfizer (PFE) have to pay Moderna damages because they infringed on Moderna's mRNA patents. The court ordered BNTX and PFE to ...

The ruling required both PFE and BNTX to compensate the company, though the final amount will be determined in further proceedings. The dispute centered around Moderna’s patent, which Pfizer and ...